AI and Drug Development: IP and data protection challenges

Insights and Analysis

AI and Drug Development: IP and data protection challenges - Webinar recording

19 December 2019

On Tuesday 19 November, a panel from our London life sciences team presented a webinar on what you need to know when using AI tools in drug development, in order to best protect your invention from an IP perspective, and avoid falling foul of EU and UK data protection laws.

Artificial intelligence (AI) is not new to the life sciences industry but its use in drug development is rapidly growing, as life sciences companies increasingly recognize the benefits of using AI at all stages of the drug development lifecycle.

In this Q&A session, our in-house scientists Marion Palmer and Rachel Gribben discuss the way in which AI is currently being used by the life sciences industry.

Imogen Ireland answers questions on the intellectual property issues arising from using AI in the drug design phase to identify novel compounds for therapeutic uses. For example, whether an AI-derived invention can be patented.

Lilly Taranto answers questions on the challenges from a data protection perspective of using AI tools in the later stages of the drug development lifecycle, from clinical trials through to analysing the success of the drug using patient data.

You can access the recording here